Small Interfering RNA Targeting Mitochondrial Calcium Uniporter Improves Cardiomyocyte Cell Viability in Hypoxia/Reoxygenation Injury by Reducing Calcium Overload

Oxidative Medicine and Cellular Longevity

Volumn 2017, Issue , 2017, Pages

  Oropeza Almazán, Yuriana ^a   Vázquez Garza, Eduardo ^a   Chapoy Villanueva, Héctor ^a   Torre Amione, Guillermo ^a,b,c   García Rivas, Gerardo ^a,b  

^a ESCUELA DE MEDICINA Y CIENCIAS DE LA SALUD   (Mexico)

^b HOSPITAL ZAMBRANO HELLION   (Mexico)

^c HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DEATH; MICROCONTROLLERS;

CALCIUM OVERLOAD; CELL VIABILITY; CELLULAR INJURY; INTRACELLULAR CA; MITOCHONDRIAL CALCIUM UNIPORTER; MITOCHONDRIAL DYSFUNCTION; SMALL INTERFERING RNA; THERAPEUTIC STRATEGY;

CALCIUM;

CALCIUM; SMALL INTERFERING RNA; CALCIUM CHANNEL; CYCLOSPORIN; MESSENGER RNA; MITOCHONDRIAL CALCIUM UNIPORTER; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CARDIAC MUSCLE CELL; CELL DAMAGE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; GENE TARGETING; HYPOXIA; IN VITRO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL PERMEABILITY; NONHUMAN; OXIDATIVE STRESS; RAT; REOXYGENATION; REPERFUSION INJURY; WESTERN BLOTTING; ANIMAL; CELL HYPOXIA; CELL LINE; CELL SURVIVAL; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; GENETICS; METABOLISM; MITOCHONDRION; MYOCARDIAL ISCHEMIA REPERFUSION INJURY; PATHOLOGY; RNA INTERFERENCE;

CALCIUM; CELLS; NUCLEIC ACIDS;

ANIMALS; APOPTOSIS; CALCIUM; CALCIUM CHANNELS; CELL HYPOXIA; CELL LINE; CELL SURVIVAL; CYCLOSPORINE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; MYOCARDIAL REPERFUSION INJURY; MYOCYTES, CARDIAC; OXIDATIVE STRESS; RATS; REACTIVE OXYGEN SPECIES; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 85015781648     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2017/5750897     Document Type: Article

References (47)

1. D. J. Hausenloy, E. A. Boston-Griffiths, and D. M. Yellon, "Cyclosporin A and cardioprotection: frominvestigative tool to therapeutic agent," British Journal of Pharmacology, vol. 165, no. 5, pp. 1235-1245, 2012.
2. D. M. Yellon and D. J. Hausenloy, "Myocardial reperfusion injury," The New England Journal of Medicine, vol. 357, no. 11, pp. 1121-1135, 2007.
3. S.-M. Kang, S. Lim, H. Song et al., "Allopurinolmodulates reactive oxygen species generation and Ca 2+ overload in ischemiareperfused heart and hypoxia-reoxygenated cardiomyocytes," European Journal of Pharmacology, vol. 535, no. 1-3, pp. 212-219, 2006.
4. A. P. Halestrap, "Mitochondria and reperfusion injury of the heart-a holey death but not beyond salvation," Journal of Bioenergetics and Biomembranes, vol. 41,no. 2, pp. 113-121, 2009.
5. A. P. Halestrap, "What is the mitochondrial permeability transition pore" Journal of Molecular and Cellular Cardiology, vol. 46, no. 6, pp. 821-831, 2009.
6. G. D. J. Garcá-Rivas, A. Guerrero-Hernández, G. Guerrero-Serna, J. S. Rodríguez-Zavala, and C. Zazueta, "Inhibition of the mitochondrial calcium uniporter by the oxo-bridged dinuclear ruthenium amine complex (Ru360) prevents from irreversible injury in postischemic rat heart," FEBS Journal, vol. 272, no. 13, pp. 3477-3488, 2005.
7. M. A. Matlib, Z. Zhou, S. Knight et al., "Oxygen-bridged dinuclear ruthenium amine complex specifically inhibits Ca2+ uptake into mitochondria in vitro and in situ in single cardiac myocytes," Journal of Biological Chemistry, vol. 273, no. 17, pp. 10223-10231, 1998.
8. E. J. Griffiths, C. J. Ocampo, J. S. Savage, M. D. Stern, and H. S. Silverman, "Protective effects of low and high doses of cyclosporin A against reoxygenation injury in isolated rat cardiomyocytes are associated with differential effects on mitochondrial calcium levels," Cell Calcium, vol. 27, no. 2, pp. 87-95, 2000.
9. G. J. Garcá-Rivas, K. Carvajal, F. Correa, and C. Zazueta, "Ru360, a specific mitochondrial calcium uptake inhibitor, improves cardiac post-ischaemic functional recovery in rats in vivo," British Journal of Pharmacology, vol. 149, no. 7, pp. 829-837, 2006.
10. F. Correa, V. Soto, and C. Zazueta, "Mitochondrial permeability transition relevance for apoptotic triggering in the postischemic heart,"The International Journal of Biochemistry&Cell Biology, vol. 39, no. 4, pp. 787-798, 2007.
11. J. M. Baughman, F. Perocchi, H. S. Girgis et al., "Integrative genomics identifies MCU as an essential component of the mitochondrial calcium uniporter," Nature, vol. 476, no. 7360, pp. 341-345, 2011.
12. D. De Stefani, A. Raffaello, E. Teardo, I. Szabó, and R. Rizzuto, "A forty-kilodalton protein of the inner membrane is the mitochondrial calcium uniporter," Nature, vol. 476, no. 7360, pp. 336-340, 2011.
13. D. De Stefani, R. Rizzuto, and T. Pozzan, "Enjoy the trip: calcium in mitochondria back and forth," Annual Review of Biochemistry, vol. 85, pp. 161-192, 2016.
14. J. Q. Kwong, X. Lu, R. N. Correll et al., "The mitochondrial calciumuniporter selectivelymatches metabolic output to acute contractile stress in the heart," Cell Reports, vol. 12, no. 1, pp. 15-22, 2015.
15. T. S. Luongo, J. P. Lambert, A. Yuan et al., "The mitochondrial calciumuniportermatches energetic supply with cardiac workload during stress and modulates permeability transition," Cell Reports, vol. 12, no. 1, pp. 23-34, 2015.
16. C.-F. Xu and J.Wang, "Delivery systems for siRNA drug development in cancer therapy," Asian Journal of Pharmaceutical Sciences, vol. 10, no. 1, pp. 1-12, 2015.
17. J. E. Zuckerman and M. E. Davis, "Clinical experiences with systemically administered siRNA-based therapeutics in cancer," Nature Reviews Drug Discovery, vol. 14, no. 12, pp. 843-856, 2015.
18. M. Patron, V. Checchetto, A. Raffaello et al., "MICU1 and MICU2 finely tune the mitochondrial Ca2+ uniporter by exerting opposite effects onMCUactivity,"Molecular Cell, vol. 53,no. 5, pp. 726-737, 2014.
19. K. A. P. Oliveira, K. G. Zecchin, L. C. Alberici, R. F. Castilho, and A. E. Vercesi, "Simvastatin inducing PC3 prostate cancer cell necrosis mediated by calcineurin and mitochondrial dysfunction," Journal of Bioenergetics and Biomembranes, vol. 40, no. 4, pp. 307-314, 2008.
20. P. Mukhopadhyay, M. Rajesh, K. Yoshihiro, G. Haskó, and P. Pacher, "Simple quantitative detection of mitochondrial superoxide production in live cells," Biochemical and Biophysical Research Communications, vol. 358, no. 1, pp. 203-208, 2007.
21. M. Zhao, L. Sun, X.-J. Yu et al., "Acetylcholine mediates AMPK-dependent autophagic cytoprotection in H9c2 cells during hypoxia/reoxygenation injury," Cellular Physiology and Biochemistry, vol. 32, no. 3, pp. 601-613, 2013.
22. P. Bernardi, F. Di Lisa, F. Fogolari, and G. Lippe, "From ATP to PTP and back: A dual function for The mitochondrial ATP synthase," Circulation Research, vol. 116, no. 11, pp. 1850-1862, 2015.
23. C. Mammucari, A. Raffaello, D. V. Reane, and R. Rizzuto, "Molecular structure and pathophysiological roles of the Mitochondrial Calcium Uniporter," Biochimica et Biophysica Acta- Molecular Cell Research, vol. 1863, no. 10, pp. 2457-2464, 2016.
24. M. Luo and M. E. Anderson, "Mechanisms of altered Ca2+ handling in heart failure," Circulation Research, vol. 113, no. 6, pp. 690-708, 2013.
25. B. S. Jhun, J. Mishra, S. Monaco et al., "The mitochondrial Ca2+ uniporter: regulation by auxiliary subunits and signal transduction pathways," American Journal of Physiology-Cell Physiology, vol. 311, no. 1, pp. C67-C80, 2016.
26. X. Luo, I. Budihardjo, H. Zou, C. Slaughter, and X.Wang, "Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors," Cell, vol. 94, no. 4, pp. 481-490, 1998.
27. T. P. Rasmussen, Y. Wu, M.-L. A. Joiner et al., "Inhibition of MCU forces extramitochondrial adaptations governing physiological and pathological stress responses in heart," Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 29, pp. 9129-9134, 2015.
28. S.-Z. Zhang, Q. Gao, C.-M. Cao, I. C. Bruce, and Q. Xia, "Involvement of the mitochondrial calcium uniporter in cardioprotection by ischemic preconditioning," Life Sciences, vol. 78, no. 7, pp. 738-745, 2006.
29. D. J. Hausenloy and D. M. Yellon, "Survival kinases in ischemic preconditioning and postconditioning," Cardiovascular Research, vol. 70, no. 2, pp. 240-253, 2006.
30. X. Pan, J. Liu, T. Nguyen et al., "The physiological role of mitochondrial calcium revealed by mice lacking the mitochondrial calciumuniporter," Nature Cell Biology, vol. 15, no. 12, pp. 1464-1472, 2013.
31. E. Murphy, X. Pan, T. Nguyen, J. Liu, K. M. Holmström, and T. Finkel, "Unresolved questions from the analysis of mice lackingMCU expression," Biochemical and Biophysical Research Communications, vol. 449, no. 4, pp. 384-385, 2014.
32. F.Di Lisa, M. Campesan, T. Zaglia, D. De Stefani, M. Mongillo, and R. Rizzuto, "Mitochondrial Ca2+ and ROS formation in cardiac injury and protection," Biochimica et Biophysica Acta (BBA)-Bioenergetics, vol. 1857, p. e11, 2016.
33. D. J. Hausenloy, H. L. Maddock, G. F. Baxter, and D. M. Yellon, "Inhibiting mitochondrial permeability transition pore opening: A new paradigm for myocardial preconditioning" Cardiovascular Research, vol. 55, no. 3, pp. 534-543, 2002.
34. S. Y. Lim, D. J. Hausenloy, S. Arjun et al., "Mitochondrial cyclophilin-D as a potential therapeutic target for postmyocardial infarction heart failure," Journal of Cellular and Molecular Medicine, vol. 15, no. 11, pp. 2443-2451, 2011.
35. A.-C. Wei, T. Liu, S. Cortassa, R. L.Winslow, and B. O'Rourke, "Mitochondrial Ca2+ influx and efflux rates in guinea pig cardiac mitochondria: low and high affinity effects of cyclosporine A," Biochimica et Biophysica Acta-Molecular Cell Research, vol. 1813, no. 7, pp. 1373-1381, 2011.
36. P. Z. Gerczuk and R. A. Kloner, "An update on cardioprotection: A review of the latest adjunctive therapies to limit myocardial infarction size in clinical trials," Journal of the American College of Cardiology, vol. 59, no. 11, pp. 969-978, 2012.
37. K. Song, S. Wang, and D. Qi, "Effects of cyclosporine on reperfusion injury in patients: A meta-analysis of randomized controlled trials," Oxidative Medicine and Cellular Longevity, vol. 2015, Article ID 287058, 6 pages, 2015.
38. A. P. Halestrap and P. Pasdois, "The role of the mitochondrial permeability transition pore in heart disease," Biochimica et Biophysica Acta-Bioenergetics, vol. 1787, no. 11, pp. 1402-1415, 2009.
39. K. Shintani-Ishida, M. Inui, and K.-I. Yoshida, "Ischemiareperfusion induces myocardial infarction through mitochondrial Ca2+ overload," Journal of Molecular and Cellular Cardiology, vol. 53, no. 2, pp. 233-239, 2012.
40. G. Santulli, W. Xie, S. R. Reiken, and A. R. Marks, "Mitochondrial calcium overload is a key determinant in heart failure," Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 36, pp. 11389-11394, 2015.
41. E. Fernández-Sada,C. Silva-Platas, C. A.Villegas et al., "Cardiac responses to -adrenoceptor stimulation is partly dependent on mitochondrial calcium uniporter activity," British Journal of Pharmacology, vol. 171, no. 18, pp. 4207-4221, 2014.
42. D. Kim and J. Rossi, "RNA mechanisms and applications," Biotechniques, vol. 44, pp. 613-616, 2009.
43. B. A. Sullenger and S. Nair, "From the RNA world to the clinic," Science, vol. 352, no. 6292, pp. 1417-1420, 2016.
44. F. Alexis, E. Pridgen, L. K. Molnar, and O. C. Farokhzad, "Factors affecting the clearance and biodistribution of polymeric nanoparticles," Molecular Pharmaceutics, vol. 5, no. 4, pp. 505-515, 2008.
45. K.Whitehead, R. Langer, and D. Anderson, "Knocking down barriers: Advances in siRNA delivery," Nature Reviews Drug Discovery, vol. 8, pp. 129-138, 2009.
46. W. G. Roberts and G. E. Palade, "Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor," Journal of Cell Science, vol. 108, no. 6, pp. 2369-2379, 1995.
47. G. U. Ruiz-Esparza, V. Segura-Ibarra, A. M. Cordero-Reyes et al., "A specifically designed nanoconstruct associates, internalizes, traffics in cardiovascular cells, and accumulates in failing myocardium: A new strategy for heart failure diagnostics and therapeutics," European Journal of Heart Failure, vol. 18, no. 2, pp. 169-178, 2016.